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Abstract 
Background. New patterns in epidemiological characteristics of people living with HIV infection (PLWH) 
and the introduction of Highly Active Antiretroviral Therapy (HAART) have changed the profile of hospital 
admissions in this population. The aim of this study was to evaluate trends in hospital admissions, re-
admissions, and mortality rates in HIV patients and to analyze the role of HCV co-infection. 
Methods. A retrospective cohort study conducted on all hospital admissions of HIV patients between 1993 
and 2013. The study time was divided in two periods (1993–2002 and 2003–2013) to be compared by 
conducting a comparative cross-sectional analysis. 
Results. A total of 22,901 patient-years were included in the analysis, with 6917 hospital admissions, 
corresponding to 1937 subjects (75% male, mean age 36 ± 11 years, 37% HIV/HCV co-infected patients). 
The median length of hospital stay was 8 days (5–16), and the 30-day hospital re-admission rate was 20.1%. 
A significant decrease in hospital admissions related with infectious and psychiatric diseases was observed in 
the last period (2003–2013), but there was an increase in those related with malignancies, cardiovascular, 
gastrointestinal, and chronic respiratory diseases. In-hospital mortality remained high (6.8% in the first period 
vs. 6.3% in the second one), with a progressive increase of non-AIDS-defining illness deaths (37.9% vs. 
68.3%, P < .001). The admission rate significantly dropped after 1996 (4.9% yearly), but it was less 
pronounced in HCV co-infected patients (1.7% yearly). 
Conclusions. Hospital admissions due to infectious and psychiatric disorders have decreased, with a 
significant increase in non-AIDS-defining malignancies, cardiovascular, and chronic respiratory diseases. In-
hospital mortality is currently still high, but mainly because of non-AIDS-defining illnesses. HCV co-
infection increased the hospital stay and re-admissions during the study period. 
  
Resumen 
Introducción. Los cambios en las características epidemiológicas de los pacientes con infección por el VIH, y 
la introducción del tratamiento antirretroviral de alta eficacia, han modificado el perfil de las 
hospitalizaciones en esta población. El objetivo del estudio fue evaluar las tendencias en hospitalización, 
reingreso y mortalidad en pacientes VIH, y analizar el papel de la coinfección por el VHC. 
Métodos. Estudio de cohortes retrospectivo, que incluyó todas las hospitalizaciones de pacientes VIH entre 
1993-2013. El estudio fue dividido en 2 periodos (1993-2002 y 2003-2013) para ser comparados mediante un 
análisis transversal. 
Resultados. Se analizaron 22.901 pacientes/años, que presentaron 6.917 hospitalizaciones que 
correspondieron a 1.937 pacientes (75% varones, edad media 36 ± 11 años, 37% coinfectados VIH/VHC). La 
mediana de estancia hospitalaria fue de 8 días (5-16), y la tasa de reingreso a los 30 días del 20,1%. Se 
observó un descenso significativo en el segundo periodo (2003-2013) de las hospitalizaciones motivadas por 
enfermedades infecciosas y trastornos psiquiátricos, y un incremento de aquellas relacionadas con neoplasias, 
enfermedad cardiovascular, gastrointestinal y enfermedades respiratorias crónicas. La mortalidad 
intrahospitalaria permanece elevada (6,8% en el primer periodo vs. 6,3% en el segundo), con un aumento 
progresivo de las muertes por enfermedades no definitorias de sida (37,9 vs. 68,3%; p < 0,001). La tasa de 
hospitalización disminuyó de manera significativa después de 1996 (4,9% anual), pero este descenso fue 
menos acusado en los pacientes coinfectados VIH/VHC (1,7% anual). 
Conclusiones. Las hospitalizaciones motivadas por enfermedades infecciosas y trastornos psiquiátricos han 
descendido; por el contrario, se observó un aumento significativo de aquellas relacionadas con neoplasias no 
definitorias de sida, enfermedad cardiovascular y enfermedades respiratorias crónicas. La mortalidad 
intrahospitalaria permanece a día de hoy elevada, pero a expensas fundamentalmente de enfermedades no 
definitorias de sida. La coinfección VIH/VHC incrementó los días de hospitalización y los reingresos durante 
el periodo de estudio. 
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Background 
Since the introduction of Highly Active Antiretroviral Therapy (HAART) in 1996, the profile 
of people living with HIV infection (PLWH) has changed significantly; with an appreciable 
decline of mortality related to AIDS-defining diseases and an improvement in life expectancy. 
However, the incidence of other comorbidities, mainly cardiovascular diseases and non-AIDS 
tumors has increased, due to the longer life expectancy, aging and persistent inflammation related 
to the HIV-infection, even in a context of long-term suppression of viremia.
1; 2; 3; 4 ;  5
 
 
From a public health perspective, it is important to understand trends and characteristics of 
hospitalizations, re-admissions and mortality rates among PLWH. However, there are few 
available data among too heterogeneous study populations in different socioeconomic contexts and 
Health Care systems. In the general population, 30-days readmission rates are increasingly 
becoming a benchmark for hospital quality of care and costs, also for PLWH.
6
 
 
The causes of hospitalizations have been changing in the HAART era. AIDS defining illnesses 
are less represented nowadays, but patients are older with more comorbidities. Therefore, the 
reasons for hospitalizations incidence, mortality and readmission rates might be changing.
6; 7; 8; 
9 ;  10
 
 
Chronic hepatitis C virus (HCV) coinfection is common in PLWH (30–50% according to 
different series).
11
 It is estimated that at least 30% of patients with HCV develop cirrhosis and 
around 1–4% of these will develop hepatocellular carcinoma. The risk of progression of liver 
disease is 2–6 times higher in HIV/HCV coinfected than in HCV mono-infected patients, which 
involves a high-related morbidity and mortality.
12; 13; 14; 15 ;  16
 However, the risk of hepatic 
decompensation and progression of liver fibrosis is drastically reduced with treatment and cure of 
HCV infection.
17 ;  18
 
 
In this context, the aim of this study was to analyze trends in hospitalization, re-admission and 
mortality rates in PLWH followed in a reference hospital in Northwest Spain in the last 20 years. 
Moreover, the impact of HCV coinfection in the dynamic of all these parameters was also 
evaluated. 
Methods 
The Complexo Hospitalario Universitario de A Coruña (CHUAC) is a 1422-bed, full service, 
24 h ICU availability, tertiary acute university care hospital, serving in the Northwest of Spain. 
The influence population in 2013 was 547,776 citizens, and that year reported 40,869 admissions 
(21% scheduled). The HIV and Hepatitis Viral Unit offers outpatient and inpatient medical care to 
all PLWH in this reference area, attending more than 1400 PLWH by HIV-trained doctors. PLWH 
are not attended in other hospitals in this area. 
Data collection 
All hospital admissions of HIV-infected patients at CHUAC between 1993 and 2013 were 
obtained through the Hospital-coding Department. Hospitalization reasons were collected 
following the International Classification of Diseases, Ninth Revision (ICD-9). Several steps were 
taken in assigning each hospitalization to a single diagnostic category. To determine the reliably 
ICD-9 code the first listed referring to neither HIV (042, V08, 795.71, V01.79) nor chronic 
hepatitis C (070.44, 070.54, 070.70, 070.71) nor oral candidiasis (120.0) was defined as the 
primary code for hospitalization. These codes represent comorbidities that are not, by themselves, 
sufficient to justify hospitalization. Recurrent bacterial pneumonia was defined as a bacterial 
pneumonia admission occurring within >30 but <365 days of a previous such admission. 
Hospitalizations whose first ICD-9 code was chemotherapeutic treatment were assigned to the first 
code based on the type of cancer. Clinical Classification Software (CCS), developed by the 
Agency for Healthcare Research and Quality
19
 was used to assign primary ICD-9 code into one of 
18 first-level categories. Finally, using a method similar to one it has previously employed,
7
 CCS 
classification was modified and categories were pooled together at major syndromes for further 
analysis. 
 
Epidemiological and clinical data related to hospitalizations and mortality were recorded. 
HIV/HCV coinfection was considered if RNA-HCV viral load was detectable. Mean length of 
hospital stay was evaluated by subtracting the date of discharge – the date of admission and adding 
1. For patients that were discharged the day of admission, it was considered 1. Re-admission was 
defined as hospitalization occurred before 30 days after discharge. Years of active outpatient care 
were defined by having at least one HIV clinician visit and one measured CD4 cell count. 
Scheduled admissions were considered if the patient were not in the Emergency Department prior 
to hospitalization. Death due to an AIDS-defining illness was defined as death attributable to one 
of the Centers for Disease Control Prevention (CDC) category C diseases. Death due to non AIDS-
defining illness was classified according to CoDe protocol (“Coding of Death in HIV”, in 
www.cphiv.dk/CoDe). 
 
The study is in accordance with the community standards and approved by the ethics 
committee. The study's protocol was reviewed and approved by the Medical Ethics Committee of 
the University Hospital of Galicia. All clinical data were anonymous and de-identified prior to 
analyze, the identification numbers of the patients were recorded blindly.  
Statistical analyses 
Hospitalization rate was evaluated as number of hospitalizations per 100 patients. For the 
denominator, the number of patients in care each year in the HIV clinic, was used; it was collected 
from medical records and electronic database of patients in follow up. The study was divided in 
two periods of time (1993–2002 and 2003–2013) to be compared with a comparative cross-
sectional analysis. 
 
Quantitative data were reported using means ± standard deviations (SD) or median (range), as 
indicated. For qualitative variables, absolute numbers and percentages were computed. The 
comparison of quantitative parameters was carried out using Student's t test. The association of 
qualitative variables was carried out using Chi-squared statistic; the relative risk (RR) was 
calculated. A two-sided type I error of 5% was considered statistically significant. 
 
A time-trend joinpoint regression analysis was performed. This technique provides the 
estimated annual percent change (APC) and allows detecting points in time at which significant 
changes in the trends occur. For each APC estimate, 95% confidence interval was also calculated. 
Statistical analysis was performed using SPSS for Windows (version 19.0, SPSS Inc., Chicago, 
IL). 
Results 
Demographic characteristics and hospitalization parameters 
A total of 2498 PLWH were followed during the period study, contributing to 22,901 patient-
years (PY). In the study period 6917 hospital admissions were recorded, corresponding to 1937 
subjects. Of them, 75.0% were male, mean age (at first hospitalization) was 36.4 ± 10.6 years, and 
37.2% were HIV/HCV coinfected. Among those PLWH hospitalized, 789 (40.7%) have one 
admission; the median number of admission was 2 (IQR: 1–4). The hospitalization rate showed a 
reduction from 30.7/100 patients (CI95%: 27.7–33.8) in 1993 to 19.9/100 patients (17.7–22.2) in 
2013 (P < .001); Fig. 1 shows the hospitalization and mortality each year and the number of 
patients on follow-up. 
 
 
 
Fig. 1. Hospitalization in PLWH between 1993 and 2013; black area indicates mortality (%). 
Patients on follow-up each year. 
In the comparative analysis between both periods (1993–2002 vs. 2003–2013), differences in 
hospitalization reasons were recognized among periods (Table 1). The main 5 reasons for 
hospitalization were: pneumonia (10.5%), chronic pulmonary disease/respiratory failure (8.3%), 
tuberculosis (7.4%), hepatic decompensation (6.3%) and psychiatric disorder/drug-abuse (5.3%). 
Overall, 23.1% of the total of 6917 hospitalizations was AIDS-defining illnesses, with differences 
between first (28.0%) and second period (16.2%), P < .001. 
Table 1. Baseline characteristics of 6917 hospital admissions between periods (1993–2002 and 2003–2013). 
 
1993–2002 (N = 3463) 2003–2013 (N = 3454) Relative change (%) (CI 95%) 
    
Scheduled admissions (%) 42.1 26.8 −36.3 (−40.5; −31.9) 
Length of stay (median, IQR) 9.0 (5.0–16.0) 8.0 (4.0–15.0) −9.9 (−18.7; 2.8) 
Re-admission (%) 19.8 20.4 3.0 (−9.2; 13.2) 
Mortality (%) 6.8 6.3 −7.0 (−22.1; 18.1) 
Hospitalization reasons (%) 
 Infectious diseases 49.1 35.3 −28.1 (−32.0; −23.9) 
  Aids-defining infections 52.3 36.5 −30.2 (−36.0; −23.9) 
 Psyquiatric illness 9.1 5.2 −42.7 (−52.0; −31.6) 
 Malignancies 3.6 7.8 115.8 (75.4; 165.3) 
  Aids-defining tumors 65.2 42.6 −34.8 (−46.0; −21.2) 
 Cardiac diseases 1.2 3.7 205.6 (116.3; 331.6) 
 Digestive system diseases 9.2 16.1 74.8 (53.6; 98.9) 
 Hepatic decompensations 4.2 8.5 103.3 (67.6; 146.6) 
 Chronic respiratory diseases 5.6 11.0 96.4 (66.3; 131.9) 
Hospitalization units (%) 
 Internal medicine/infectious diseases 85.0 70.8 −16.7 (−18.9; −14.5) 
 Surgical units 5.0 10.4 108.0 (74.6; 147.9) 
 Onco-hematology 2.0 4.3 116.5 (63.4; 186.9) 
 Gynecology/obstetrics 2.7 4.3 58.9 (23.3; 104.9) 
 Pediatrics 1.5 0.3 −80.7 (−90.2; −62.1) 
 Intensive care unit 2.0 6.0 200.8 (130.0; 293.4) 
Cause of in-hospital death (%) 235/453 218/453 
 
 AIDS related illness: 62.1 31.7 −49.0 (−59.1; −36.6) 
  Aids related encephalopatya 17.0 5.0 −70.4 (−84.4; −43.7) 
  MAI-MTB infectionb 15.3 6.0 −61.1 (−78.8; −28.6) 
  Pneumocistis jirovecci pneumonia 11.5 6.0 −48.1 (−72.5; −2.0) 
  Aids related malignancy 8.5 11.0 29.4 (−26.4; 127.4) 
  Disseminated candidiasis 3.8 0.5 −88.0 (−98.5; −6.2) 
  Recurrent bacterial pneumoniae 3.4 1.8 −46.1 (−83.5; 76.5) 
  Wasting syndrome 2.6 1.4 46.1 (−86.3; 112.9) 
 Non-AIDS related illness: 37.9 68.3 80.5 (49.7; 117.6) 
  (02.1) Bacterial infectionc 10.2 17.0 66.2 (2.9; 168.4) 
  (02.1.1) Bacterial infection with sepsis 6.8 12.8 88.6 (5.0; 238.9) 
  (03.1.1) HCV with cirrhosis 5.1 11.0 115.6 (10.5; 320.5) 
  (04) Malignancyd 2.6 9.6 277.3 (55.2; 817.3) 
  (16)Violent death/(19)substance abuse 3.4 1.4 −59.6 (−89.1; 50.4) 
  (9) Stroke and (23) other CNS disease 3.4 5.5 61.7 (−32.6; 288.0) 
  (13) Chronic obstructive lung diseasee 2.6 7.8 205.4 (22.7; 660.5) 
  (08) MI and other heart disease 0.4 1.4 223.4 (−66.1; 2985.6) 
  (90) Other causes 3.4 1.8 −46.1 (−83.5; 76.5) 
    
 
Main causes of in-hospital mortality. 
Statistically significant results (P < .05) are shown in bold. 
a Including progressive multifocal leukoencephalopathy, cryptococcal meningitis and cerebral toxoplasmosis. 
b Micobacterium Avium Intracellulare and Micobacterium Tuberculosis. 
c Only due to pneumonia. 
d Including hepatocarcinoma. 
e Including other chronic respiratory diseases. 
Re-admissions and mortality rates by clinical units 
Overall, 5759 (83.3%) were considered primary hospitalizations, 998 (14.4%) were first re-
admissions and 160 (2.3%) were subsequent re-admissions in a chain. The median length of 
hospital stay was 8.0 days (5.0–16.0). 
 
The re-admission rate was 20.1% (CI95%: 19.1–21.2) without differences by gender (20.3% in 
men vs. 19.7% in women, P = .21). Mean age of patients in hospitalizations without a re-
admission (37.4 ± 10.4) was similar than those re-admitted (37.9 ± 10.9 years). A higher rate of re-
admissions was observed for some services such as Onco-Hematology (68.5%), Gynecology–
Obstetrics (24.2%), Internal Medicine-Infectious Diseases (20.0%) or Pediatric Unit (16.3%). 
Those with lower rate were: surgery units (13.2%) or Psychiatry Unit (8.2%). Main reasons for 
hospital admission have different re-admission rates: tumoral diseases 33.8%, hepatic 
decompensations 23.5%, chronic pulmonary diseases 20.8%, infectious diseases 18.9%, 
cardiovascular diseases 14.9%, and psychiatric disorders 12.8%. 
 
Between 1993–2013, 453 in-hospital deaths were identified, with an overall inpatient mortality 
rate of 6.5% (CI95%: 6.0–7.1). Globally, the mortality of hospitalizations for males was higher 
than for women (7.4% vs. 4.4%, RR: 1.7 [1.3–2.1], P < .001). Mean age of patients who died 
during the hospitalizations was 40.1 ± 11.3 years, significantly higher (P < .001) than that of those 
who did not die (37.3 ± 10.4 years). Mortality of primary hospitalizations was 5.7% vs. 11.0% 
among re-admissions (RR 1.93 [1.59–2.35], P < .001). AIDS-defining illnesses hospitalizations 
presented a mortality of 13.4%, while in non AIDS-defining diseases was 4.5% (RR: 3.0 [2.5–3.6], 
P < .001). 
 
There were differences in mortality rate by Units (P = .005): Onco-Hematology (12.4%), 
Internal Medicine-Infectious Diseases (6.7%), Surgery (3.6%) and Pediatric (3.5%). No patient's 
death in Gynecology–Obstetrics or Psychiatry Unit. There were 24 hospitalizations admitted in 
ICU directly from the Emergency Department, 21 of them (87.5%), died during the ICU stay. 
Hospitalizations that were admitted in ICU (whenever during the hospitalization) had higher 
mortality rate (35.5%) than those without ICU care (5.3%) (RR 6.6 [5.5–8.0], P < .001). The main 
causes of in-patient death and the change between both periods are detailed in Table 1. 
HIV/HCV coinfection 
A total of 716 HIV/HCV coinfected patients were hospitalized at least once during the study 
period, giving a total of 3525 hospitalizations (1408 between 1993–2002 and 2117 between 2003–
2013). Fig. 2 depicts the changes in incidence during the follow up. In the joinpoint regression 
analysis, two different trends were observed. Hospitalizations rate increased between 1993 and 
1996 in all cohort (APC = 11.8%). Between 1997 and 2013, hospitalizations rate decreased much 
more in HIV mono-infected (APC = −4.9%) than in HIV/HCV coinfected (APC = −1.7%), 
P < .001. 
 
 
 
Fig. 2. Hospitalization rate in HIV/HCV coinfected and HIV monoinfected patients. Joinpoint 
regression analysis: trends in hospitalizations in HIV/HCV coinfected and HIV monoinfected 
patients. Estimated Annual percent change (bold if statistically significant, P < .001 in all cases). 
In comparison between HIV/HCV coinfected and HIV monoinfected patients, P = .65 in the first 
period (1993–1996) and P < .001 in the second (1996–2013). 
Overall, the mean length of stay in HCV coinfected patients was similar than in mono-infected 
(median: 10.1 days [6.3–15.9] vs. 11.0 [6.0–19.5], P = .24); but coinfected had more 
hospitalizations per patient (median: 3.0 [1.0–6.0] vs. 2.0 [1.0–3.0], P < .001) and higher 
readmission rates (21.5% vs. 19.1%, RR: 1.1 [1.0–1.2], P < .001). The sum of total days of 
hospitalization per patient during the follow-up was higher among HIV/HCV coinfected than in 
HIV mono-infected (median: 36.0 days [14.0–77.5] vs. 23.0 days [9.0–51.0], respectively; 
P < .001). 
 
The main causes of hospitalization in coinfected patients, comparatively with HIV-
monoinfected, are illustrated in Fig. 3. A decrease of infectious diseases and psychiatric disorders 
was evidenced. On the other hand, an important increase in hospitalizations due to hepatic 
decompensations was found (from 5.8% to 11.5%, RR: 2.0 [CI95%: 1.5–2.6], P < .001). 
  
 
 
 
Fig. 3. Main reasons of hospital admission (a) and in-hospital mortality (b) in HIV-
mono and HIV/HCV-coinfected patients during 1993–2002 and 2003–2013. 
Mortality rate of hospitalizations in HIV/HCV coinfected increases from 4.0% (1993–2002) to 
6.2% (2003–2013), RR = 1.5 (1.1–2.1, P < .001). There were also differences in mortality reasons: 
infectious diseases mortality decreased significantly (RR = .6 [.4–.9], P < .001), tumors increased 
(RR = 2.1 [.5–8.8], P = .01) and hepatic decompensations also increased from 15.6% to 21.2% 
(RR: 1.4 [.6–3.3], P = .005) (Fig. 3). 
Discussion 
This study evaluates trends in hospitalizations among PLWH in a medical reference area of 
Northwest Spain. Overall, the hospitalizations rate showed a decline from 31/100 patients in 1993 
to 20/100 patients in 2013, but remains higher than in the general population. These results are 
concordant with other previously published in different countries and different Health Care 
Systems.
6 ;  21
 The joinpoint analysis established a point of change in 1996. This behavior is related 
with the introduction of HAART and its rapid impact in AIDS-defining illnesses. In this year, the 
trend of hospitalization incidence changed from a yearly growing of 11.8% toward a yearly 
decreasing of 3.4%. 
 
Changes in the reasons of hospital admission were also observed between the two periods 
evaluated. Thus, a significant decrease in hospitalizations due to infectious (mainly AIDS-defining 
diseases) and psychiatric disease or drugs abuse was recognized in contrast to a progressive 
increase of malignancies specially those non AIDS-defining, chronic respiratory, cardiovascular 
and liver related diseases. Overall, hospitalizations due to AIDS-defining diseases dropped (from 
28.0% to 16.2%) in our cohort, but their mortality did not change significantly (15.0% in 1993–
2003 and 12.3% in 2004–2013). AIDS-defining diseases and their high mortality remain a current 
problem worldwide; this problem must be addressed from the universalization of HAART and 
improving the diagnostic strategies.
7
 
 
Accordingly, changes in hospitalization units were also observed. Thus, in the second period 
there was an increase in hospitalizations in surgical areas and onco-haematologic units, likely due 
to an increase in the life expectancy among HIV-infected patients in the second period because the 
access to specific treatments as for the general population. The rates of ICU admissions increased 
up to 3-times, probably caused by the same reasons. 
 
However, the average length of stay and re-admission rates remain high, similar to those 
reflected in other studies,
10 ;  20
 probably due to an increase in the comorbidities associated with 
HIV infection, that involve greater complexity of clinical management in this group of patients. 
Despite the improvement in the care of PLWH, the in-hospital mortality remains high; in this 
cohort the mortality in men is 1.7 times higher than in women, according to data published 
previously.
21 ;  22
 Non-AIDS deaths increased significantly during the ART era and nowadays are 
the main cause of in-hospital mortality in PLWH. Non-AIDS infections, cirrhosis and its 
complications, and malignancies were major contributors to mortality. Non-AIDS mortality 
increased by 80.5% between first and second period; consequently, AIDS mortality decreased by 
49.0%. Cowell et al., reported similar trends recently, in a huge American cohort.
23
 
 
The 30 days re-admission rate in our cohort was 20.1%, similar to data recently reported by 
Berry et al. (19.3%).
6
 The re-admission rate has an important impact on long-term health and 
mortality rate of PLWH. Indeed, some mathematical models are developed to predict re-
admission, but they need to be validated in other populations.
24
 
 
Within this cohort, nearly 40% were HIV/HCV coinfected patients. They had more 
hospitalizations, re-admissions and the sum of the total stays were significantly greater than for 
HIV mono-infected, similarly to that previously published.
16
 Interestingly, the incidence of 
hospitalizations in 2013 was double in coinfected compared to HIV mono-infected. Indeed, 
although the hospitalization rate decreases since 1996, the APC is near to three times higher in 
mono-infected than in coinfected. Therefore, in terms of hospitalizations and in-hospital mortality, 
HCV coinfection seems to mask the beneficial effect of HAART and improvements in HIV care, 
although other factors such IDU or alcohol could also play a significant role. Hospitalizations due 
to hepatic decompensation are double in the last ten years (2003–2013) compared with the first 
period (1993–2002). Moreover, Meyers et al. described recently that HCV mortality appears to be 
relatively stable while total HIV/AIDS deaths are on a decline across the state of Massachusetts in 
a trend analysis of HIV and HCV using multiple cause of death.
25
 All these data suggest that 
hospitalizations, decompensations and mortality will increase in the next years if HCV infection is 
not eradicated. The impact of a wide access to new anti-HCV therapies in HIV-infected patients 
must be evaluated in the near future.
26; 27 ;  28
 
 
There are some limitations in our study that merit discussion. This is a retrospective 
observational study, using data recorded from a single hospital that it could affect the 
generalizability of our finding. However, this is a reference hospital with more than 1000-beds and 
a large cohort of HIV- and HCV-infected patients in follow-up in this institution since the 
beginning of both epidemics. Although there are not other HIV outpatient clinics in our area, some 
patients had an admission without any follow up in our clinic; it could overestimate hospitalization 
rates. Moreover, there are some variables that might be also associated with mortality that were 
not collected (i.e. smoking, or years under HAART exposure) and therefore its specific impact in 
hospitalizations and rates of mortality could not be analyzed. Data of CD4 count, HAART and 
viral suppression were not available, the effect of this important factors in PLWH was not 
analyzed. Patients admitted in Onco-Hematology Units to receive scheduled chemotherapy (12%) 
could overestimate the hospitalization rate in these Units and underestimate the in-hospital 
mortality in them. The study did not include HCV-infected patients treated with new DAAs based 
therapies, neither a control group of hospitalized HIV-negative patients. Finally, it is possible that 
the use of the ICD-9 coding system might introduce coding errors, although minority. 
 
In summary, in this large cohort of PLWH, followed during 20 years, a decrease in the 
hospitalizations rate and a progressive decline of AIDS defining illnesses have been recognized. 
Consequently, chronic comorbidities and malignancies have been increasing within the last ten 
years. However, the length of stay, re-admission and the mortality rate remains high. HCV 
coinfection has a negative impact in these parameters and is associated with increases in the 
morbidity and mortality and therefore in the resource consumption among PLWH. These findings 
are essential to improve and optimize the clinical management of PLWH and to pay special 
attention in those comorbidities that favor the hospitalization and mortality rates nowadays. 
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